May 30th 2023
Comprehensive insights on unmet needs, ongoing research, and the future of advanced ovarian cancer treatment.
Expert oncologists review the current PARP inhibitor treatment indications for patients with advanced ovarian cancer and discuss how to best manage patients who have been impacted by the recent updates to the PARP inhibitors.
Drs Coleman and Monk discuss what led to the recent withdrawal of several indications for PARP inhibitors in the treatment of advanced ovarian cancer.
Expert oncologists give an overview of PARP inhibitors available for the treatment of patients with advanced ovarian cancer and review adverse events seen with each agent.
Experts on advanced ovarian cancer give detailed insights on the role of biomarker testing and identify important biomarkers.
Robert L Coleman, MD, FACOG, FACS, and Bradley J Monk, MD, FACOG, FACS, provide an overview of advanced ovarian cancer and discuss its prevalence and diagnosis process.
March 27th 2023
Robert L. Coleman, MD, FACOG, FACS, discusses an analysis of the phase 3 SORAYA trial evaluating response rates in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine at different points in their disease course.
November 17th 2022
The panel closes their discussion by highlighting their favorite news or update from recent conferences, including ESMO 2022.
Dr Shannon Westin explains the data on treatment of rare tumors in ovarian cancer and why biomarker testing is essential.
November 10th 2022
A key opinion leader reviews data on novel investigational agents for recurrent ovarian cancer.
Drs Coleman and Westin continue the discussion of antibody-drug conjugates for treatment of ovarian cancer.
November 4th 2022
Dr Michael Birrer highlights updated data on antibody-drug conjugates in ovarian cancer treatment.
Dr Shannon Westin shares if and when she could justify withholding a PARP inhibitor from a patient with HRD-positive ovarian cancer.
October 27th 2022
Experts discuss the best approach to treating patients with ovarian cancer who are resistant to PARP inhibitors.
A look at the maintenance treatment strategies for advanced or metastatic ovarian cancer.
October 20th 2022
Michael J. Birrer, MD, PhD, explains the reasoning for combining PARP inhibitors with immunotherapy in ovarian cancer treatment, highlighting ongoing trials.
Robert L. Coleman, MD, FACOG, FACS, describes data updates from the PRIMA trial investigating PARP inhibition in HRD-negative ovarian cancer populations.
October 17th 2022
Dr Michael Birrer reviews data from the PAOLA-1 trial investigating bevacizumab combination therapy for frontline maintenance therapy in advanced ovarian cancer.
Bradley J. Monk, MD, FACOG, FACS, generates a discussion on the use of PARP inhibitors in ovarian cancer treatment.
October 6th 2022
Shannon N. Westin, MD, MPH, FACOG, explains the study design and outcomes of the SOLO-3 trial.